{
    "clinical_study": {
        "@rank": "57166", 
        "acronym": "EAGLE", 
        "arm_group": {
            "arm_group_label": "Eculizumab", 
            "arm_group_type": "Experimental", 
            "description": "Patient Body weight \u226540 kg: initial phase 900 mg weekly x 4 and maintenance phase 1200 mg at week 5; then 1200 mg every 2 weeks Patient Body weight 30 - <40 kg : initial phase 600 mg weekly x 2 and maintenance phase 900 mg at week 3; then 900 mg every 2 weeks"
        }, 
        "brief_summary": {
            "textblock": "Membranoproliferative glomerulonephritis (MPGN) is the third or fourth leading cause of end\n      stage renal disease among the primary glomerulonephritis. Hyperactivation of the alternative\n      complement pathway and familial forms for all types of MPGN have been reported suggesting\n      that genetic abnormalities may play a predisposing role to the disease. In recent case\n      reports Eculizumab, a monoclonal antibody that binds to C5 to prevent formation of the\n      membrane attack complex ,is a safe and effective therapy."
        }, 
        "brief_title": "Eculizumab in Primary MPGN", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Membranoproliferative Glomerulonephritis", 
        "condition_browse": {
            "mesh_term": [
                "Glomerulonephritis", 
                "Glomerulonephritis, Membranoproliferative"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Biopsy-proven primary MPGN\n\n          -  Creatinine clearance >20 ml/min per 1.73m2\n\n          -  24-hour proteinuria persistently exceeding 3,5g in adults or exceeding 40mg/h/m2 in\n             children (or exceeding 2mg protein/mg creatinine in children spot urine samples)\n\n          -  Persistently low C3 levels in at least two consecutive evaluations\n\n          -  Persistently high sC5b9 levels (>1000 ng/ml) in at least two previous consecutive\n             evaluations\n\n          -  Written informed consent (by parents or tutors if underage)\n\n        Exclusion Criteria:\n\n          -  Age \u226575 years\n\n          -  Secondary MPGN (evidence of infection, immunological disease including vasculitis,\n             systemic diseases and proliferative disorders)\n\n          -  Evidence at kidney biopsy evaluation of severe chronic histological changes that very\n             unlikely could benefit of eculizumab therapy\n\n          -  Concomitant steroid or immunosuppressive therapy for immuno-mediated disease\n\n          -  Pregnancy or lactating\n\n          -  Childbearing potential without effective contraception\n\n          -  Any clinically relevant condition that might affect completion of the study\n             participation and/or confound study results\n\n          -  Inability to understand the potential risks and benefits of the study\n\n          -  Legal incapacity"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 17, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02093533", 
            "org_study_id": "EAGLE", 
            "secondary_id": "2013-003826-10"
        }, 
        "intervention": {
            "arm_group_label": "Eculizumab", 
            "intervention_name": "Eculizumab", 
            "intervention_type": "Drug", 
            "other_name": "Soliris"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Membranoproliferative glomerulonephritis", 
            "Nephrotic syndrome", 
            "Proteinuria", 
            "Alternative complement pathway", 
            "Complement inhibition", 
            "Eculizumab"
        ], 
        "lastchanged_date": "March 19, 2014", 
        "location": [
            {
                "contact": {
                    "email": "giovanni.messina1952@libero.it", 
                    "last_name": "Giovanni Messina, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Bari", 
                        "country": "Italy", 
                        "state": "BA"
                    }, 
                    "name": "Ospedale Pediatrico \"Giovanni XXIII\" - U:O Nefrologia"
                }, 
                "investigator": [
                    {
                        "last_name": "Giovanni Messina, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Luisa Santangelo, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "gremuzzi@hpg23.it", 
                    "last_name": "Giuseppe Remuzzi, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Bergamo", 
                        "country": "Italy", 
                        "state": "BG"
                    }, 
                    "name": "A.O. Papa Giovanni XXIII - U.O. Nefrologia e Dialisi/IRCCS IRFMN - Centro di Ricerche Cliniche per le Malattie Rare Aldo e Cele Dacc\u00f2"
                }, 
                "investigator": [
                    {
                        "last_name": "Piero Ruggenenti, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Elena Mondo, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "giovanni.montini@aosp.bo.it", 
                    "last_name": "Giovanni Montini, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Bologna", 
                        "country": "Italy", 
                        "state": "BO"
                    }, 
                    "name": "Policlinico Sant'Orsola -Malpighi - U.O.S. Nefrologia e dialisi pediatrica"
                }, 
                "investigator": {
                    "last_name": "Giovanni Montini, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "dsantoro@unime.it", 
                    "last_name": "Domenico Santoro, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Messina", 
                        "country": "Italy", 
                        "state": "ME"
                    }, 
                    "name": "Policlinico \"G.Martino\" - U.O. Nefrologia e Dialisi"
                }, 
                "investigator": {
                    "last_name": "Domenico Santoro, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "murer@pediatria.unipd.it", 
                    "last_name": "Luisa Murer, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Padova", 
                        "country": "Italy", 
                        "state": "PD"
                    }, 
                    "name": "Policlinico Universitario di Padova - U.O. Nefrologia Pediatrica"
                }, 
                "investigator": [
                    {
                        "last_name": "Luisa Murer, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Elisabetta Benetti, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "bruno.giacon@asbz.it", 
                    "last_name": "Bruno Giacon, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Bolzano", 
                        "country": "Italy", 
                        "zip": "39100"
                    }, 
                    "name": "Ospedale Centrale"
                }, 
                "investigator": {
                    "last_name": "Bruno Giacon, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "antonio.pisani@libero.it", 
                    "last_name": "Antonio Pisani, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Napoli", 
                        "country": "Italy"
                    }, 
                    "name": "Policlinico \"Federico II\" - U.O. Nefrologia"
                }, 
                "investigator": {
                    "last_name": "Antonio Pisani, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "emma@opbg.net", 
                    "last_name": "Francesco Emma, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Roma", 
                        "country": "Italy"
                    }, 
                    "name": "Ospedale Pediatrico \"Bambin Ges\u00f9\" - U.O. Nefrologia"
                }, 
                "investigator": [
                    {
                        "last_name": "Francesco Emma, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Marina Vivarelli, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "passalacqua@aferesi.it", 
                    "last_name": "Stefano Passalacqua, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Roma", 
                        "country": "Italy"
                    }, 
                    "name": "C.I. Columbus-Universit\u00e0 Cattolica del S.Cuore - UOC Nefrologia e Dialisi"
                }, 
                "investigator": {
                    "last_name": "Stefano Passalacqua, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Rosanna Coppo, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Torino", 
                        "country": "Italy"
                    }, 
                    "name": "Presidio Ospedaliero O.I.R.M. \"Sant'Anna\" - U.O. Nefrologia"
                }, 
                "investigator": [
                    {
                        "last_name": "Rosanna Coppo, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Alessandro Amore, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "giuliano.brunori@apss.tn.it", 
                    "last_name": "Giuliano Brunori, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Trento", 
                        "country": "Italy"
                    }, 
                    "name": "Ospedale \"Santa Chiara\" - U.O. Nefrologia"
                }, 
                "investigator": {
                    "last_name": "Giuliano Brunori, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "apasi@ulss.tv.it", 
                    "last_name": "Alessandra Pasi, Md"
                }, 
                "facility": {
                    "address": {
                        "city": "Treviso", 
                        "country": "Italy"
                    }, 
                    "name": "Ospedale C\u00e0 Foncello - U.O. Nefrologia"
                }, 
                "investigator": {
                    "last_name": "Alessandra Pasi, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "1", 
        "official_title": "EVALUATING THE MORPHOFUNCTIONAL EFFECTS OF ECULIZUMAB THERAPY IN PRIMARY MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS: A PILOT, SINGLE ARM STUDY IN TEN PATIENTS WITH PERSISTENT HEAVY PROTEINURIA", 
        "other_outcome": {
            "measure": "Number of participants with Adverse Events as a measure of safety.", 
            "safety_issue": "Yes", 
            "time_frame": "Participants will be followed for the duration of the study, an expected average of 72 weeks"
        }, 
        "overall_contact": {
            "email": "piero.ruggenenti@marionegri.it", 
            "last_name": "Piero Ruggenenti, MD"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Italy: The Italian Medicines Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "24hours proteinuria", 
            "safety_issue": "No", 
            "time_frame": "Changes from baseline at week 1,12,24,36,48 and 72."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02093533"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Terminal complement complex (sC5b-9) levels", 
                "safety_issue": "No", 
                "time_frame": "Changes from baseline at 1,2, 3, 4,12,24,36,48,52,56,60 and 72 week."
            }, 
            {
                "measure": "Glomerular filtration rate (GFR) measured by iohexol plasma clearance and estimated.", 
                "safety_issue": "No", 
                "time_frame": "Changes from Baseline at 1,24, 48 and 72 week."
            }, 
            {
                "measure": "Time to disease progression.", 
                "safety_issue": "No", 
                "time_frame": "Up 72 week."
            }
        ], 
        "source": "Mario Negri Institute for Pharmacological Research", 
        "sponsors": {
            "collaborator": {
                "agency": "Alexion Pharma Italy s.r.l.", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Mario Negri Institute for Pharmacological Research", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}